Cargando…

Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors

PURPOSE: A growing body of evidence indicates that zoledronic acid (ZA) can improve the clinical outcome in patients with breast cancer and low estrogen levels. In the present study, we aimed to investigate the survival benefit of ZA administration in postmenopausal Korean women with breast cancer w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Sung Gwe, Kim, Sung Hyun, Lee, Hak Min, Lee, Seung Ah, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278054/ https://www.ncbi.nlm.nih.gov/pubmed/25548583 http://dx.doi.org/10.4048/jbc.2014.17.4.350

Ejemplares similares

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status
por: Choi, Jihye, et al.
Publicado: (2019)

Prospective Evaluation of the Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Negative Axillary Conversion after Neoadjuvant Chemotherapy
por: Lee, Hy-De, et al.
Publicado: (2015)

Prognostic Factors for Patients with Bone-Only Metastasis in Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Clinical Outcomes of Ductal Carcinoma In Situ of the Breast Treated with Partial Mastectomy without Adjuvant Radiotherapy
por: Hwang, Seung Hyun, et al.
Publicado: (2012)

Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer
por: Lee, Seung Ah, et al.
Publicado: (2018)

Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients
por: Kim, Hyung Won, et al.
Publicado: (2014)

The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Metastasis-Free Interval Is Closely Related to Tumor Characteristics and Has Prognostic Value in Breast Cancer Patients with Distant Relapse
por: Kim, Hee Jun, et al.
Publicado: (2015)

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program
por: Park, Jung Min, et al.
Publicado: (2017)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial
por: Cho, A-Ra, et al.
Publicado: (2022)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
por: Dieckmeyer, Michael, et al.
Publicado: (2019)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Local Control of Brain Metastasis: Treatment Outcome of Focal Brain Treatments in Relation to Subtypes
por: Chong, Jae Uk, et al.
Publicado: (2015)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

[18F]-Fluorodeoxyglucose Positron Emission Tomography Can Contribute to Discriminate Patients with Poor Prognosis in Hormone Receptor-Positive Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Molecular Classification of Triple-Negative Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2016)

Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

A nomogram constructed using intraoperative ex vivo shear-wave elastography precisely predicts metastasis of sentinel lymph nodes in breast cancer
por: Bae, Soong June, et al.
Publicado: (2019)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Ex Vivo Shear-Wave Elastography of Axillary Lymph Nodes to Predict Nodal Metastasis in Patients with Primary Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2018)

Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients
por: Ko, Sung Min, et al.
Publicado: (2021)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7rpb4sraiqdgdk3hrcoil1aiu5